1. Tacar, O., P. Sriamornsak, and C.R. Dass, Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. Journal of pharmacy and pharmacology, 2013. 65(2): p. 157-170.
2. Cheng, T., et al., Green tea catechin-based complex micelles combined with doxorubicin to overcome cardiotoxicity and multidrug resistance. Theranostics, 2016. 6(9): p. 1277.
3. Hu, Y.-P., N. Henry-Toulme, and J. Robert, Failure of liposomal encapsulation of doxorubicin to circumvent multidrug resistance in an in vitro model of rat glioblastoma cells. European Journal of Cancer, 1995. 31(3): p. 389-394.
4. Yang, C.S., et al., Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. Nature Reviews Cancer, 2009. 9(6): p. 429.
5. Li, W., et al., A major green tea component,(−)-epigallocatechin-3-gallate, ameliorates doxorubicin-mediated cardiotoxicity in cardiomyocytes of neonatal rats. Journal of agricultural and food chemistry, 2010. 58(16): p. 8977-8982.
6. Navarro, G., et al., P-glycoprotein silencing with siRNA delivered by DOPE-modified PEI overcomes doxorubicin resistance in breast cancer cells. Nanomedicine, 2012. 7(1): p. 65-78.
7. Jodoin, J., M. Demeule, and R. Béliveau, Inhibition of the multidrug resistance P-glycoprotein activity by green tea polyphenols. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research, 2002. 1542(1-3): p. 149-159.
8. Sesarman, A., et al., Co-delivery of curcumin and doxorubicin in PEGylated liposomes favored the antineoplastic C26 murine colon carcinoma microenvironment. Drug delivery and translational research, 2019. 9(1): p. 260-272.
9. Chatterjee, K., et al., Doxorubicin cardiomyopathy. Cardiology, 2010. 115(2): p. 155-162.
10. Friedman, M., Overview of antibacterial, antitoxin, antiviral, and antifungal activities of tea flavonoids and teas. Molecular nutrition & food research, 2007. 51(1): p. 116-134.
11. Xiang, L.-P., et al., Suppressive effects of tea catechins on breast cancer. Nutrients, 2016. 8(8): p. 458.
12. Tsai, L.-C., et al., EGCG/gelatin-doxorubicin gold nanoparticles enhance therapeutic efficacy of doxorubicin for prostate cancer treatment. Nanomedicine, 2016. 11(1): p. 9-30.
13. Gu, J.-W., et al., EGCG, a major green tea catechin suppresses breast tumor angiogenesis and growth via inhibiting the activation of HIF-1α and NFκB, and VEGF expression. Vascular cell, 2013. 5(1): p. 9.
14. Stearns, M.E., et al., Combination therapy with epigallocatechin-3-gallate and doxorubicin in human prostate tumor modeling studies: inhibition of metastatic tumor growth in severe combined immunodeficiency mice. The American journal of pathology, 2010. 177(6): p. 3169-3179.
15. Ray, L., P. Kumar, and K.C. Gupta, The activity against Ehrlich's ascites tumors of doxorubicin contained in self assembled, cell receptor targeted nanoparticle with simultaneous oral delivery of the green tea polyphenol epigallocatechin-3-gallate. Biomaterials, 2013. 34(12): p. 3064-3076.